Aguech-Oueslati Leïla, Jaidane Hela, Sane Famara, Jrad-Battikh Nedia, Hamed Sabrine Ben, Hober Didier, Gharbi Jawhar
Unité de Recherche UR17ES30 "Génomique, Biotechnologie et Stratégies Antivirales»", Institut Supérieur de Biotechnologie, Université de Monastir, BP74, Avenue Tahar Hadded, 5000, Monastir, Tunisia.
et CHU de Lille Laboratoire de Virologie, Université de Lille, EA3610, 59037, Lille, France.
Curr Microbiol. 2018 Jan;75(1):32-39. doi: 10.1007/s00284-017-1347-2. Epub 2017 Aug 30.
Coxsackie B4 (CV-B4), is a major cause of viral myocarditis, dilated cardiomyopathy, and pancreatitis. Like other human enteroviruses, CV-B4 is ubiquitous, excreted in the stool, transmitted by fecal-oral route, and persists in the environment. In the context of studies on CV-B4 infection, it is important to investigate how this virus can be eliminated and to show the possibility of contamination risk with a CV-B4 E2 infected Swiss albino mice. Swiss albino female mice were inoculated with CV-B4 E2 strain and divided in two groups: the first was intraperitoneally (I.P.) infected; the second was orally infected. In order to study the CV-B4 E2 infection in mice, total RNA was extracted from thymus, spleen, pancreas, and intestine, and viral genome was detected using semi-nested (RT-PCR). To further demonstrate infection or immunization of mice, Sera obtained from infected mice were assayed in vitro for their neutralizing antibody. To detect virus in stool of infected mice, stool samples were collected at different post-infection (p.i.) times. Neutralizing antibodies were detectable all along the follow-up period (Day 0, 1, 3, 7, 9, 17, 22, 30, 45, 60 p.i.) in I.P and oral infected mice. Our results showed that when mice were inoculated successively at day 0 and day 8, neutralizing activity was increased in I.P route more than in the oral route. Viral isolation in HEp-2 cells showed negative results. Stool viral analyses reveal a low detection of the CV-B4 E2 genome for all infected mice. In conclusion, our experiments demonstrated that there are no risks linked with the stool of CV-B4 E2 of Swiss albino mice. It would be interesting to characterize the inhibitors of the virus infectivity in these biological samples (stool) and investigate their targets and mechanisms of action.
柯萨奇B4病毒(CV-B4)是病毒性心肌炎、扩张型心肌病和胰腺炎的主要病因。与其他人类肠道病毒一样,CV-B4广泛存在,通过粪便排出,经粪口途径传播,并在环境中持续存在。在关于CV-B4感染的研究中,重要的是研究如何消除这种病毒,并展示CV-B4 E2感染的瑞士白化小鼠存在污染风险的可能性。将瑞士白化雌性小鼠接种CV-B4 E2毒株并分为两组:第一组进行腹腔内(I.P.)感染;第二组进行口服感染。为了研究小鼠中的CV-B4 E2感染,从胸腺、脾脏、胰腺和肠道中提取总RNA,并使用半巢式(RT-PCR)检测病毒基因组。为了进一步证明小鼠的感染或免疫情况,对感染小鼠的血清进行体外中和抗体检测。为了检测感染小鼠粪便中的病毒,在感染后的不同时间(p.i.)收集粪便样本。在腹腔内和口服感染的小鼠的整个随访期(感染后第0、1、3、7、9、17、22、30、45、60天)都可检测到中和抗体。我们的结果表明,当小鼠在第0天和第8天连续接种时,腹腔内途径的中和活性比口服途径增加得更多。在HEp-2细胞中的病毒分离显示为阴性结果。粪便病毒分析显示,所有感染小鼠的CV-B4 E2基因组检测率较低。总之,我们的实验表明,瑞士白化小鼠的CV-B4 E2粪便不存在相关风险。表征这些生物样本(粪便)中病毒感染性的抑制剂,并研究其靶点和作用机制将是很有趣的。